Asia-Pacific: Medicaments Containing Insulin Market 2024

Medicaments Containing Insulin Market Size in Asia-Pacific

The Asia-Pacific medicaments containing insulin market soared to $X in 2023, surging by X% against the previous year. In general, consumption, however, saw a perceptible slump. Over the period under review, the market reached the peak level at $X in 2012; however, from 2013 to 2023, consumption failed to regain momentum.

Medicaments Containing Insulin Production in Asia-Pacific

In value terms, medicaments containing insulin production reached $X in 2023 estimated in export price. Overall, production continues to indicate a relatively flat trend pattern. The pace of growth appeared the most rapid in 2017 when the production volume increased by X%. The level of production peaked in 2023 and is expected to retain growth in the immediate term.

Join Us at HANNOVER MESSE 2024

Don’t miss your chance to connect with us directly. Schedule a personal meeting to dive deeper into how solutions.
Hall 002, Stand C10. 22 - 26 April 2024 | Hannover, Germany

Book Your Meeting

Medicaments Containing Insulin Exports

Exports in Asia-Pacific

In 2023, approx. X tons of medicaments containing insulin but not antibiotics were exported in Asia-Pacific; with a decrease of X% on the previous year's figure. Overall, exports saw a deep slump. The pace of growth appeared the most rapid in 2020 when exports increased by X% against the previous year. The volume of export peaked at X tons in 2013; however, from 2014 to 2023, the exports remained at a lower figure.

In value terms, medicaments containing insulin exports reduced remarkably to $X in 2023. Over the period under review, exports saw a deep slump. The growth pace was the most rapid in 2020 when exports increased by X% against the previous year. Over the period under review, the exports hit record highs at $X in 2013; however, from 2014 to 2023, the exports remained at a lower figure.

Exports by Country

China was the largest exporting country with an export of about X tons, which finished at X% of total exports. New Zealand (X tons) took the second position in the ranking, distantly followed by Hong Kong SAR (X tons) and Thailand (X tons). All these countries together took approx. X% share of total exports.

Exports from China increased at an average annual rate of X% from 2012 to 2023. At the same time, New Zealand (X%), Hong Kong SAR (X%) and Thailand (X%) displayed positive paces of growth. Moreover, New Zealand emerged as the fastest-growing exporter exported in Asia-Pacific, with a CAGR of X% from 2012-2023. From 2012 to 2023, the share of China, New Zealand, Hong Kong SAR and Thailand increased by X, X, X and X percentage points, while the shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, New Zealand ($X) remains the largest medicaments containing insulin supplier in Asia-Pacific, comprising X% of total exports. The second position in the ranking was held by Hong Kong SAR ($X), with an X% share of total exports. It was followed by China, with a X% share.

From 2012 to 2023, the average annual growth rate of value in New Zealand totaled X%. The remaining exporting countries recorded the following average annual rates of exports growth: Hong Kong SAR (X% per year) and China (X% per year).

Export Prices by Country

The export price in Asia-Pacific stood at $X per ton in 2023, surging by X% against the previous year. Overall, the export price, however, showed a abrupt descent. The most prominent rate of growth was recorded in 2016 an increase of X%. As a result, the export price attained the peak level of $X per ton. From 2017 to 2023, the export prices remained at a somewhat lower figure.

There were significant differences in the average prices amongst the major exporting countries. In 2023, amid the top suppliers, the country with the highest price was New Zealand ($X per ton), while China ($X per ton) was amongst the lowest.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by New Zealand (X%), while the other leaders experienced mixed trends in the export price figures.

Medicaments Containing Insulin Imports

Imports in Asia-Pacific

In 2023, imports of medicaments containing insulin but not antibiotics in Asia-Pacific fell to X tons, dropping by X% on 2022. Over the period under review, imports saw a abrupt decline. The most prominent rate of growth was recorded in 2017 with an increase of X%. The volume of import peaked at X tons in 2018; however, from 2019 to 2023, imports remained at a lower figure.

In value terms, medicaments containing insulin imports dropped dramatically to $X in 2023. In general, imports, however, showed a relatively flat trend pattern. The pace of growth was the most pronounced in 2022 with an increase of X%. As a result, imports reached the peak of $X, and then contracted sharply in the following year.

Imports by Country

In 2023, Myanmar (X tons) was the main importer of medicaments containing insulin but not antibiotics, comprising X% of total imports. Timor-Leste (X kg) took the second position in the ranking, followed by Fiji (X kg), Australia (X kg) and Samoa (X kg). All these countries together held approx. X% share of total imports. New Zealand (X kg), Solomon Islands (X kg), New Caledonia (X kg), Nepal (X kg), Tonga (X kg), Sri Lanka (X kg) and French Polynesia (X kg) followed a long way behind the leaders.

Myanmar was also the fastest-growing in terms of the medicaments containing insulin but not antibiotics imports, with a CAGR of X% from 2012 to 2023. At the same time, Australia (X%), New Zealand (X%), Sri Lanka (X%), Tonga (X%), French Polynesia (X%), Timor-Leste (X%), Nepal (X%), Solomon Islands (X%) and Samoa (X%) displayed positive paces of growth. By contrast, New Caledonia (X%) and Fiji (X%) illustrated a downward trend over the same period. From 2012 to 2023, the share of Myanmar, Timor-Leste, Australia, Samoa, New Zealand, Fiji, Solomon Islands, Tonga, Sri Lanka, Nepal, New Caledonia and French Polynesia increased by X, X, X, X, X, X, X, X, X, X, X and X percentage points, while the shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, Myanmar ($X) constitutes the largest market for imported medicaments containing insulin but not antibiotics in Asia-Pacific, comprising X% of total imports. The second position in the ranking was taken by Fiji ($X), with an X% share of total imports. It was followed by New Caledonia, with a X% share.

In Myanmar, medicaments containing insulin imports increased at an average annual rate of X% over the period from 2012-2023. The remaining importing countries recorded the following average annual rates of imports growth: Fiji (X% per year) and New Caledonia (X% per year).

Import Prices by Country

In 2023, the import price in Asia-Pacific amounted to $X per ton, waning by X% against the previous year. Overall, the import price, however, saw a resilient expansion. The pace of growth was the most pronounced in 2019 an increase of X%. The level of import peaked at $X per ton in 2022, and then reduced sharply in the following year.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was New Caledonia ($X per ton), while Sri Lanka ($X per ton) was amongst the lowest.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by Timor-Leste (X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform